Login to Your Account

Pharma: Other News To Note

Friday, March 30, 2012
• Forest Laboratories Inc., of New York, and Almirall SA, of Barcelona, Spain, said the FDA will require a three-month extension to complete its review of the new drug application for aclidinium bromide, a long-acting antimuscarinic drug, for the maintenance treatment of chronic obstructive pulmonary disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription